Robert Dworkin, Ph.D. Joins Lotus Clinical Research as Director, Chronic Pain Research to lead Lotus’ chronic pain research programs Lotus Clinical Research, a specialty analgesic full-service CRO, has announced the addition of Robert (Bob) Dworkin, Ph.D. as...
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug...
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that...
In a pioneering clinical trial that will attack Alzheimer’s disease by targeting inflammation in the brain’s blood vessels, researchers at the George & Anne Ryan Institute for Neuroscience have received regulatory approval to initiate the BEACON Study. This...
Sound Pharmaceuticals (SPI) is pleased to announce that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with SPI-1005 is aimed to prevent and treat ototoxicity in Cystic Fibrosis (CF) patients...
Email
Text